Revolutionizing Drug Development: AI-Designed Medicines to Begin Human Trials by 2025

Colin Murdock, president of Isomorphic Labs (a sister company of Google DeepMind, also part of the Alphabet group), shared with Fortune that his company intends to begin testing the first AI-designed drugs on volunteers by the end of 2025. “Our Kings Cross office in London is home to teams working alongside AI to develop cancer therapies,” Murdock stated during an interview in Paris. “This is happening right now.” The company’s immediate objective is to initiate clinical trials as swiftly as possible, collaborating with pharmaceutical giants Novartis and Eli Lilly.

Isomorphic Labs was founded following the breakthrough of AlphaFold 2, for which Google DeepMind co-founder Demis Hassabis and lead developer John Jumper were awarded the 2024 Nobel Prize in Chemistry. This model was the first to predict the three-dimensional structures of 98.5% of human proteins, making its findings accessible to researchers worldwide. Subsequently, AlphaFold 3 was released, capable not only of predicting protein shapes but also of modeling their interactions with DNA, RNA, ions, antibodies, and drug molecules.

The Isomorphic Labs platform utilizes AlphaFold 3 to generate a pool of potential drug candidates, select the most promising ones, which are then synthesized in collaboration with their partner laboratories (Novartis and Eli Lilly). In traditional practices, these processes take 3 to 5 years; however, Isomorphic Labs aims to reduce this timeline to just a few months, potentially tailoring drugs to individual patients, thus maximizing effectiveness and minimizing side effects.

The candidate drugs developed in this manner will still undergo preclinical and three phases of clinical testing before receiving FDA approval, a typically lengthy process of 5 to 7 years. However, for personalized medications, only the primary platform needs to obtain approval, allowing for swift validation of versions tailored to specific patients.

P.S. You can support me by subscribing to the channel «the runaway neural network«, where I discuss AI from a creative perspective.